Bryan McGurn, Sr. VP of Sales & Marketing Discusses IMI’s Impact In The Healthcare Domain

Evaluating IMI’s contributions to healthcare systems and specialty pharmacies alike through highly valued partnerships, advocating for customers’ voices, and adapting to new standards.

Released August 2022

Q: Diversion poses a significant risk to the healthcare systems, what role does IMI play in aiding facilities to combat this costly problem?

IMI has had a long-standing focus on developing products that significantly deter unauthorized access to the medication supply chain. Our Prep-Lock™ tamper-evident product family protects a variety of drug containers from potential misuse by offering both visual and physical barriers to those seeking an easy avenue to divert drugs and has become a valuable staple in any system’s overall drug security protocols. Our commitment to this cause does not end with our products. IMI is an active supporter of advocacy groups such as the International Health Facility Diversion Association (IHFDA) and the National Association of Drug Diversion Investigators (NADDI).

Q: Are tamper-evident products a requirement?

Ever since the intentional tampering of a commercial drug product, which led to patient deaths in the early 1980s, drug manufacturers and government legislators have introduced strong measures to mitigate such recurrences. It is no surprise that when IMI introduced its tamper-evident cap for I.V. syringes shortly thereafter, the product exploded in popularity within the drug compounding community. Today, more pressure from hospital risk management and strong recommendations from accreditation associations have brought about the further adoption of these products to improve patient safety.

Prep-Lock Tamper Evident Cap

Q: How do IMI Products impact (contribute to) patient safety?

It becomes very obvious when you consider the total impact of a compromised drug. First, a drug that has been illicitly siphoned from its container may rob a patient of their intended dose. In the case of pain medication, this can substantially reduce the patient’s well-being. But the concern goes beyond that. Once that same container has been opened prior to its intended use, the chances of introducing contamination to the drug increase exponentially. This can lead to patient infection and other complications. These two reasons alone are enough to justify the use of tamper-evident products. When you consider the total cost involved in the aftermath of these events, it becomes very clear that these products are an essential component of any drug security program.

Q: IMI Tamper Evident products seem to be very popular within the outsource Compounding space. What solutions does IMI offer for health systems and specialty pharmacies?

The reason that IMI tamper-evident products are used by over 80% of the 503b Compounders should be the same reason why any compounding operation would use IMI products…Drug security and drug integrity. Compounded drug preparations are always in transit once they leave the pharmacy. The only way to ensure this medication reaches the intended patient without mishap or compromise is through the use of tamper-evident products. IMI makes it very easy to incorporate our products as part of the pharmacy workflow. We offer bulk entry packaging options to increase efficiency and reduce cost. Our products are developed by listening to the voice of the compounding pharmacist and delivering solutions to their concerns.

Q: The Industry is adopting a new device connector standard (ENFit) for Enteral Medications. What is IMI’s role in the transition?

IMI remains in front of the changing standards impacting the healthcare system. The ENFit connector standard is no exception. We offer the first and only tamper-evident cap product to protect syringes that comply with this connector standard. IMI is an active member of the Global Enteral Device Supplier Association (GEDSA). The organization drives the adoption of new connector standards designed to mitigate potentially harmful misconnections between various drug delivery lines, such as ENFit and the upcoming NRFit standard.

The Cap That Protects Children

Q: Technology in the healthcare space is rapidly evolving. How is IMI innovating with the times?

IMI recognizes that it is not enough to deliver high-quality, cost-effective products. That’s why we continually innovate to address the changing technological landscape. Our new tamper-evident products with RFID are a prime example. IMI, in partnership with DoseID, is paving the way to meet the growing inventory control challenges within health systems. Our tamper-evident caps with RFID work seamlessly with DoseID-compatible inventory control systems. We make it easy to add RFID to your syringe products by doing what you should already be doing…applying an IMI tamper evident cap. There is no need to buy secondary RFID labels, installation equipment, or develop new processes or workflows. Simply install our tamper evident cap with the incorporated DoseID RFID tag.

Nurse holding 57-70 RFID Cap for oral syringes
ENFit Cap Featuring RFID Small Technology

Q: How are IMI sterile compounding products different from others in the market?

Many of the topics we have discussed here exemplify IMI’s leadership position in secure drug delivery devices. Our pursuit of ongoing product innovation combined with attention to our customers has been a key to our success. In a day and age of supply chain disruptions and unstable international sources, IMI is proud to offer products that are “Made in USA.” We believe that these attributes make us uniquely qualified to be the reliable partner to pharmacists and compounding operations throughout America.

You Might Also Be Interested In Reading:

The Cap That Protects Children

The Cap That Protects ChildrenThe cap that protects children – Children’s Hospital of Alabama bolsters secure drug delivery with the integration of IMI’s Tamper-Evident Caps for Enfit Syringes.Julie Lasseigne, PharmD Pediatric Pharmacy Director ~ Children’s Hospital...

International Medical Industries Releases Tamper Evident Caps with Incorporated RFID

IMI (International Medical Industries, Inc.) bolsters expertise in secure drug delivery products with the release of their Prep-Lock Tamper Evident Cap for IV Syringes with incorporated Radio Frequency Identification (RFID) technology.

Tamper-Evident Caps with RFID Combat Diversion in Healthcare

The Staggering Cost of DiversionA recent study published in the Journal of Hospital Medicine cited the vast costs diversion poses for Health Systems. “Hospitals bear the cost of diverted drugs, internal investigations, and follow-up care for affected patients, and can...

IMI Brings Expertise in Tamper Evident Security to Home Health

IMI brings expertise in Tamper Evident Security to the home health market through a strategic partnership with
Integrated Medical Systems, Inc. (IMS), a leading national distributor within the alternate site marketplace. The
collaboration introduces IMI products to home infusion healthcare furthering drug integrity and security from
pharmacy to patient

Trends in Ensuring Safety for Home Infusion: The Case for Tamper-Evident Products

To ensure safety throughout the supply chain and in the patient’s home, providers are adopting tamper-evident products for intravenous home infusion.

To better understand the steps home infusion providers are taking to ensure safety, Becker’s Hospital Review recently spoke with Neil Colby, RPh, an infusion pharmacist and Director of Infusion Pharmacy Services for CDRx Infusion

Ensuring Medication Safety with Tamper Evident Products

The Substance Abuse and Mental Health Services Administration and American Nurses Association estimate that 10% of health care workers experience substance abuse, given the access to medications in health care institutions. One report estimates that, in 2019, 148 million medication doses were diverted by health care employees.

What Are You Doing To Prevent Drug Diversion?

the record $7.75 million penalty for allegations of inappropriate pharmacy operations involving drug diversion. The Investigation by Drug Enforcement Officials uncovered irregularities concerning the distribution, dispensing, and record keeping of controlled substances…

IMI Joins DoseID

International Medical Industries, Inc. has joined DoseID, a consortium comprised of industry-leading manufacturers, hospitals, automation vendors, software vendors, and Outsourced Compounders. Through the development of and administration of comprehensive industry...

Official Coronavirus Statement

Official Covid19 StatementIMI Statement Regarding Supply and Saefty of Products In Light of Coronavirus OutbreakIMI recognizes the challenges brought about by  the Coronavirus outbreak. We are taking aggressive measures to fortify our  supply chain and insure our...

IMI Awarded MDSAP Certification

IMI is pleased to announce that it has received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP). This accomplishment exemplifies IMI ability to provide safe and effective medical...

We offer complimentary evaluation samples.

Complete the form below to request yours now.

Have questions about what a partnership with IMI can do for your organization? What more information on a product or pricing? Fill out the form below and one of our specialists will get back to you as soon as possible (usually within one business day).